Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAB NYSE:CPHI NASDAQ:MDCX NASDAQ:TVGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCABBioAtla$4.58+9.3%$3.94$3.12▼$71.50$7.59M0.7650,154 shs135,554 shsCPHIChina Pharma$0.68-4.9%$0.73$0.38▼$2.03$27.66M1.14170,461 shs126,978 shsMDCXMedicus Pharma$0.46+10.5%$0.35$0.25▼$3.69$26.06M-0.053.91 million shs950,497 shsTVGNTevogen Bio$5.86+1.6%$8.46$4.14▼$71.00$24.54M0.228,022 shs3,418 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCABBioAtla0.00%+13.86%+25.83%-25.84%-77.95%CPHIChina Pharma0.00%+16.79%+0.14%+17.42%-60.98%MDCXMedicus Pharma0.00%-9.10%+18.94%-15.20%-87.68%TVGNTevogen Bio0.00%-17.57%-44.89%+16.10%-90.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCABBioAtla$4.58+9.3%$3.94$3.12▼$71.50$7.59M0.7650,154 shs135,554 shsCPHIChina Pharma$0.68-4.9%$0.73$0.38▼$2.03$27.66M1.14170,461 shs126,978 shsMDCXMedicus Pharma$0.46+10.5%$0.35$0.25▼$3.69$26.06M-0.053.91 million shs950,497 shsTVGNTevogen Bio$5.86+1.6%$8.46$4.14▼$71.00$24.54M0.228,022 shs3,418 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCABBioAtla0.00%+13.86%+25.83%-25.84%-77.95%CPHIChina Pharma0.00%+16.79%+0.14%+17.42%-60.98%MDCXMedicus Pharma0.00%-9.10%+18.94%-15.20%-87.68%TVGNTevogen Bio0.00%-17.57%-44.89%+16.10%-90.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCABBioAtla 2.00Hold$200.004,266.81% UpsideCPHIChina Pharma 0.00N/AN/AN/AMDCXMedicus Pharma 2.25Hold$9.001,856.52% UpsideTVGNTevogen Bio 1.50Reduce$100.001,606.48% UpsideCurrent Analyst Ratings BreakdownLatest BCAB, CPHI, MDCX, and TVGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026BCABBioAtla Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026MDCXMedicus Pharma Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/20/2026TVGNTevogen Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026MDCXMedicus Pharma D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.004/10/2026MDCXMedicus Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCABBioAtla$2M3.79N/AN/A($28.51) per share-0.16CPHIChina Pharma$3.99M6.93N/AN/A$0.70 per share0.98MDCXMedicus PharmaN/AN/AN/AN/AN/AN/ATVGNTevogen BioN/AN/AN/AN/A($211.84) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCABBioAtla-$59.61M-$41.72N/AN/AN/AN/AN/A-325.64%8/6/2026 (Estimated)CPHIChina Pharma-$3.08M-$0.55N/AN/AN/A-85.56%-63.93%-31.42%N/AMDCXMedicus Pharma-$35.46M-$2.68N/AN/AN/AN/A-3,137.84%-311.33%8/10/2026 (Estimated)TVGNTevogen Bio-$26.27M-$4.61N/AN/AN/AN/AN/A-472.77%8/13/2026 (Estimated)Latest BCAB, CPHI, MDCX, and TVGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BCABBioAtla-$10.00-$4.22+$5.78-$4.22$1.72 millionN/A5/15/2026Q1 2026TVGNTevogen Bio-$2.64-$1.61+$1.03-$1.61N/AN/A5/14/2026Q1 2026MDCXMedicus Pharma-$0.18-$0.31-$0.13-$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCABBioAtlaN/AN/AN/AN/AN/ACPHIChina PharmaN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/ATVGNTevogen BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCABBioAtlaN/A0.150.15CPHIChina Pharma0.220.790.26MDCXMedicus PharmaN/A1.221.22TVGNTevogen BioN/A0.290.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCABBioAtla77.23%CPHIChina PharmaN/AMDCXMedicus PharmaN/ATVGNTevogen BioN/AInsider OwnershipCompanyInsider OwnershipBCABBioAtla9.34%CPHIChina Pharma6.40%MDCXMedicus Pharma8.10%TVGNTevogen Bio70.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCABBioAtla601.66 million1.50 millionOptionableCPHIChina Pharma25040.52 million15.92 millionNot OptionableMDCXMedicus PharmaN/A56.66 million52.07 millionN/ATVGNTevogen Bio34.19 million1.24 millionN/ABCAB, CPHI, MDCX, and TVGN HeadlinesRecent News About These CompaniesTevogen Bio (NASDAQ:TVGN) Shares Down 10.1% - Here's WhyJune 30, 2026 | americanbankingnews.comTevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services InitiativeJune 10, 2026 | finanznachrichten.deTevogen Bio Holdings Inc. Announces William Keane as Interim Head of New Healthcare Services Initiative, Exploring MSO and CRO AcquisitionsJune 9, 2026 | quiverquant.comQTevogen Announces Formation of a Healthcare Services InitiativeJune 9, 2026 | globenewswire.comTevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual RevenueMay 28, 2026 | finanznachrichten.deTevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 ...May 28, 2026 | enidnews.comETevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual RevenueMay 28, 2026 | globenewswire.comTevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services ...May 21, 2026 | caledonianrecord.comCTevogen Bio Holdings Inc. Signs Non-Binding Letter of Intent to Explore Strategic Healthcare TransactionMay 21, 2026 | quiverquant.comQTevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services OrganizationMay 21, 2026 | globenewswire.comTevogen Bio Holdings Inc. Reports Significant Operational Improvements and Strategic Growth InitiativesMay 18, 2026 | quiverquant.comQLetter to Shareholders from CEO Dr. Ryan SaadiMay 18, 2026 | globenewswire.comTevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest ...May 12, 2026 | caledonianrecord.comCTevogen Bio Holdings Inc. Secures $3 Million PIPE Financing from The Patel Family, LLPMay 12, 2026 | quiverquant.comQTevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market CloseMay 12, 2026 | globenewswire.comTevogen (TVGN) Soars 11% as Firm Gears Up for AI Training CommercializationMay 5, 2026 | finance.yahoo.comTevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application PortalApril 27, 2026 | finance.yahoo.comTevogen.AI Nears Completion of PredicTcellâ„¢ Training; Initiates Commercial Readiness and Debuts Internal Application PortalApril 27, 2026 | globenewswire.comTevogen Bio krijgt melding van Nasdaq wegens niet-naleving beursregelsApril 23, 2026 | nl.investing.comTevogen Bio Faces Nasdaq Market Value Compliance ChallengesApril 22, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCAB, CPHI, MDCX, and TVGN Company DescriptionsBioAtla NASDAQ:BCAB$4.58 +0.39 (+9.31%) Closing price 04:00 PM EasternExtended Trading$4.48 -0.10 (-2.18%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.China Pharma NYSE:CPHI$0.68 -0.04 (-4.92%) Closing price 03:59 PM EasternExtended Trading$0.65 -0.03 (-4.20%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.Medicus Pharma NASDAQ:MDCX$0.46 +0.04 (+10.50%) Closing price 04:00 PM EasternExtended Trading$0.46 0.00 (-0.43%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.Tevogen Bio NASDAQ:TVGN$5.86 +0.09 (+1.56%) Closing price 04:00 PM EasternExtended Trading$5.84 -0.02 (-0.34%) As of 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
